Note: If you attended the live CE activity on June 11, 2020 AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-20-278-L01-P), you are NOT allowed to also receive credit for the home-study on-demand web portion of this activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
As the world shifts focus to mortality reduction during the COVID-19 pandemic, clinicians may find themselves strained when managing serious bacterial infections. Gram-negative infections often appear in the most critically ill patients, and with a potential for considerable strain on ICU beds, continuing education may significantly impact outcomes. As novel antibiotics are approved, appropriate and conservative use may be essential to maintain their efficacy.
Clinical and infectious diseases professionals must have the most up to date information about the spectrum of antimicrobial activity, dosing, adverse effects, and place in therapy to guide appropriate use of new agents and information about emerging therapies on the horizon. Importantly, an analysis of which agent is approved for what indication, the gram-negative coverage profile, unique patient considerations – such as renal or hepatic impairment – and overall dosing and monitoring are critical in managing new treatments.
In part 1 of this activity, subject matter experts will discuss the knowledge and practice surrounding the use of antibiotics for gram-negative infections in an on-demand webinar. Part 2 of this activity is a podcast featuring Drs. Keith Kaye and Kim Claeys as they answer the questions viewers submitted. Listeners will benefit from this worthwhile content which focuses on empiric therapy selection, formulary, microbiology lab susceptibility testing, rapid diagnostics and dosing.
This program is intended for pharmacists and physicians who treat and manage patients with gram-negative infections.
At the completion of this activity, the participant will be able to:
- Describe the most recent epidemiological patterns in gram-negative bacterial resistance and the burden on clinical practice.
- Discuss current and emerging novel antimicrobials by gram-negative coverage, indication, dosing, and side effects.
- Identify antimicrobial stewardship principles for novel antimicrobials including place in practice, empirical use, susceptibility testing, and formulary considerations.
Kimberly C. Claeys, PharmD, BCPS
Assistant Professor Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Keith S. Kaye, MD, MPH
Professor of Internal Medicine
Director of Research, Division of Infectious Diseases
University of Michigan Medical School
Ann Arbor, Michigan
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Keith Kaye has disclosed that he has received consulting fees from Melinta, Merck and Shionogi.
- Kimberly C. Claeys has disclosed that she has served on the speakers bureau for GenMark Diagnositics and has provided study supplies for BioFire Diagnostics and GenMark Diagnotics.
ProCE Planners have reported the following financial relationships or products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:
- Melissa Johnson has disclosed that she has served on the advisory board for Astellas, Cidara, Paratek, Shionogi, and received royalties from UpToDate.
- Bruce Jones has disclosed that he has received honoraria from ALK, Allergan, Paratek and Tetraphase and grant funding from ALK.
- Lynne Fehrenbacher has no relevant conflicts of interest to report.
- Douglas Fish has no relevant conflicts of interest to report.
- CCO Staff have no relevant conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Pharmacist Release Date: June 11, 2020
Physician Release Date: August 21, 2020
Expiration Date: July 31, 2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-20-278-H01-P and 0221-9999-20-299-H01-P have been assigned to this two-part home study, knowledge-based activity (initial release date 6-11-2020). This activity is approved for 2.25 contact hours (0.225 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC and ProCE, Inc. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Clinical Care Options, LLC, 12001 Sunrise Valley Drive, Suite 300, Reston, VA
Sophia Kelley, (203)-316-2125, [email protected], www.clinicaloptions.com
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.